NUMAFERM

NUMAFERM GmbH specializes in the biotechnological production of peptides and small proteins. The Company offers its technology, related research, development services and a peptide catalog focusing on adhesive, antimicrobial and pharmaceutical peptides. NUMAFERM was founded in 2017 as a spin-off of the Institute of Biochemistry at the Heinrich Heine University in Düsseldorf by Christian Schwarz (CEO) and Philipp Bürling (CFO). The Company has since been awarded several times for its pioneering work. Investors include Prof. Detlev Riesner and Dr. Ing. Jürgen Schumacher, both co-founders of the most successful German biotech company Qiagen, the High-Tech Gründerfonds (HTGF), the European Investment Fund and Evonik Venture Capital GmbH.